Source:http://linkedlifedata.com/resource/pubmed/id/11400951
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
2001-6-12
|
| pubmed:abstractText |
We evaluated the feasibility of tandem-cycle high-dose chemotherapy (HDCT) with cisplatin, melphalan, and peripheral blood progenitor cells (PBPCs). Fifty patients with high-risk primary (n = 17) or stage IV breast cancer (n = 29) or other malignancies (n = 4) received 2 cycles of intravenous melphalan, 20 to 151.8 mg/m2, and cisplatin, 200 mg/m2, followed by granulocyte-macrophage colony-stimulating factor (GM-CSF) or G-CSF. Starting at 40 mg/m2 of melphalan, patients also received PBPCs. Delayed platelet recovery defined the maximum tolerated dose (MTD) for melphalan at 101.2 mg/m2 per cycle. There were no treatment-related deaths. Cycle 2 was delivered at a median of 1.7 months after cycle 1; 72% of patients treated at the MTD received both cycles. Cycle 2 was omitted when patients refused it or had disease progression or toxicities, primarily prolonged thrombocytopenia. Complete response rates in stage IV breast cancer patients increased from 28% pre-HDCT to 55% after cycle 2. At a median follow-up of 4.6 years (range, 1.5-8.1 years), 11 of 29 patients with stage IV breast carcinoma were alive with 5-year projected progression-free and overall survival rates of 19% (95% confidence interval [CI], 7%-41%) and 39% (95% CI, 20%-62%), respectively. Five-year projected progression-free and overall survival rates for patients with stage IV breast cancer in complete response following HDCT versus all others were 35% (95% CI, 15%-70%) versus 0% (P = .01) and 61% (95% CI, 35%-91%) versus 10% (95% CI, 2%-60%) (P = .003; log-rank test), respectively. Estrogen-receptor positivity was predictive of reduced risk of progression (relative risk [RR], 0.25; 95% CI, 0.10-0.65; P = .003) and death (RR, 0.27; 95% CI, 0.10-0.72; P = .009) after adjusting for response status. Five-year projected relapse-free and overall survival rates were 71% (95% CI, 43%-96%) and 82% (95% CI, 56%-100%), respectively, for the 17 patients with high-risk primary breast cancer. Tandem-cycle high-dose melphalan and cisplatin with PBPCs is feasible. Preliminary data suggest significant activity in selected patients with stage IV responding breast carcinoma.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
1083-8791
|
| pubmed:author |
pubmed-author:ChowWW,
pubmed-author:DoroshowHH,
pubmed-author:FormanSS,
pubmed-author:FrankenRR,
pubmed-author:HamasakiVV,
pubmed-author:LeoneNN,
pubmed-author:LongmateEE,
pubmed-author:MargolisPP,
pubmed-author:MolinaAA,
pubmed-author:MorganRRJr,
pubmed-author:O'DonnellMM,
pubmed-author:RaschkeDD,
pubmed-author:ReardonDD,
pubmed-author:ShibataSS,
pubmed-author:SmithEE,
pubmed-author:SniecinskiII,
pubmed-author:SomloGG,
pubmed-author:TetefMM,
pubmed-author:YenYY
|
| pubmed:issnType |
Print
|
| pubmed:volume |
7
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
284-93
|
| pubmed:dateRevised |
2007-11-14
|
| pubmed:meshHeading |
pubmed-meshheading:11400951-Adult,
pubmed-meshheading:11400951-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:11400951-Breast Neoplasms,
pubmed-meshheading:11400951-Cisplatin,
pubmed-meshheading:11400951-Disease-Free Survival,
pubmed-meshheading:11400951-Feasibility Studies,
pubmed-meshheading:11400951-Female,
pubmed-meshheading:11400951-Follow-Up Studies,
pubmed-meshheading:11400951-Graft Survival,
pubmed-meshheading:11400951-Granulocyte Colony-Stimulating Factor,
pubmed-meshheading:11400951-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:11400951-Humans,
pubmed-meshheading:11400951-Maximum Tolerated Dose,
pubmed-meshheading:11400951-Melphalan,
pubmed-meshheading:11400951-Middle Aged,
pubmed-meshheading:11400951-Neoplasm Staging,
pubmed-meshheading:11400951-Survival Analysis,
pubmed-meshheading:11400951-Treatment Outcome
|
| pubmed:year |
2001
|
| pubmed:articleTitle |
Tandem-cycle high-dose melphalan and cisplatin with peripheral blood progenitor cell support in patients with breast cancer and other malignancies.
|
| pubmed:affiliation |
Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, California 91010-3000, USA. gsomlo@coh.org
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.
|